Immunotherapy News and Research

Latest Immunotherapy News and Research

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Ludwig Cancer Research and Agenus Inc. today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development.

7 Mar 2014

Researcher wins grant from NCI to continue developing new therapy for bladder cancer

A biomedical engineering researcher at the University of Arkansas will use a $416,897 grant from the National Cancer Institute to continue developing a new therapy for bladder cancer.

6 Mar 2014

Novel cancer immunotherapy approach may provide new weapon against most deadly tumors

A novel approach to cancer immunotherapy - strategies designed to induce the immune system to attack cancer cells - may provide a new and cost-effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma.

6 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Merck, known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego.

5 Mar 2014

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Eisai Co., Ltd. and Biogen Idec announced today that they have entered into a collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401.

5 Mar 2014

Local hyperthermia treatment induces mechanism of anti-tumor immune resistance

A combination of iron-oxide nanoparticles and an alternating magnetic field, which together generate heat, have activated an immune system response to tumors in mice according to an accepted manuscript by Dartmouth-Hitchcock Norris Cotton Center researchers in the journal Nanomedicine: Nanotechnology, Biology and Medicine released online on February 24, 2014.

5 Mar 2014

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments.

4 Mar 2014

Dendreon plans to make PROVENGE available in Europe

Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.

3 Mar 2014

Food allergy increases among black children, say researchers

Children's food allergies are gradually increasing, but they may be as much as doubling among black children. According to a study published today in the March issue of Annals of Allergy, Asthma and Immunology, the scientific publication of the American College of Allergy, Asthma and Immunology (ACAAI), self-reported food allergy nearly doubled in black children over 23 years.

3 Mar 2014

Washington University professor to receive AACR-CRI Lloyd J. Old Award in Cancer Immunology

The American Association for Cancer Research (AACR) and the Cancer Research Institute (CRI) will present Robert D. Schreiber, Ph.D., Alumni Endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology, and Director of the Center for Human Immunology and Immunotherapy Programs at Washington University School of Medicine in St. Louis, Mo., with the second annual AACR-CRI Lloyd J. Old Award in Cancer Immunology at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9.

3 Mar 2014

Asthma drug accelerates desensitization in patients with food allergies to several foods

An asthma drug accelerates the process of desensitizing patients with food allergies to several foods at the same time, a new study by researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital Stanford shows.

3 Mar 2014

Fred Hutchinson, SCCA researchers receive Seattle Business Magazine's 2014 Leaders in Health Care Awards

Researchers at Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance (SCCA) were recognized in several categories of Seattle Business Magazine's 2014 Leaders in Health Care Awards, including the publication's Lifetime Achievement Award, given to Frederick R. Appelbaum, M.D., executive vice president and deputy director of Fred Hutch and president of SCCA.

26 Feb 2014

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera presented results of its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) this past weekend to top clinicians and scientists at the invitation-only International Association for the Study of Lung Cancer meeting on targeted therapies in Santa Monica, CA.

26 Feb 2014

NCI recommends renewal for Wistar's Support Grant with award of $14.9M

After an extensive review by a panel of top cancer experts, the National Cancer Institute (NCI) rated The Wistar Institute Cancer Center as "exceptional" and recommended renewal for Wistar's Support Grant with an award of $14.9 million over the next five years.

24 Feb 2014

Cell therapy: A powerful treatment for cancer patients

Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells.

24 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Vaccine-based clinical trial to improve survival outcomes of kidney cancer patients

The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a novel Phase III, vaccine-based clinical trial aimed at providing kidney cancer patients long-term control of their disease.

20 Feb 2014

FDA approves CSC’s Phase II clinical trial for cancer immunotherapy in women with ovarian cancer

California Stem Cell, Inc. (CSC) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company's application to begin a Phase II clinical trial exploring the potential of a patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer.

19 Feb 2014

Tel Aviv University researchers win two prestigious melanoma research awards from MRA

Tel Aviv University researchers won two out of three prestigious melanoma research awards granted this year by The Melanoma Research Alliance and The Saban Family Foundation. The Team Science Awards are the centerpiece of the MRA research fund, which seeks to promote transformational melanoma research for swift clinical implementation.

18 Feb 2014

Immunotherapy News and Research

Latest Immunotherapy News and Research

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Researcher wins grant from NCI to continue developing new therapy for bladder cancer

Novel cancer immunotherapy approach may provide new weapon against most deadly tumors

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Local hyperthermia treatment induces mechanism of anti-tumor immune resistance

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

Dendreon plans to make PROVENGE available in Europe

Food allergy increases among black children, say researchers

Washington University professor to receive AACR-CRI Lloyd J. Old Award in Cancer Immunology

Asthma drug accelerates desensitization in patients with food allergies to several foods

Fred Hutchinson, SCCA researchers receive Seattle Business Magazine's 2014 Leaders in Health Care Awards

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

NCI recommends renewal for Wistar's Support Grant with award of $14.9M

Cell therapy: A powerful treatment for cancer patients

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Vaccine-based clinical trial to improve survival outcomes of kidney cancer patients

FDA approves CSC’s Phase II clinical trial for cancer immunotherapy in women with ovarian cancer

Tel Aviv University researchers win two prestigious melanoma research awards from MRA

Event guide: 7th Allogeneic Cell Therapies Summit eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Immunotherapy News and Research

Latest Immunotherapy News and Research

Event guide: 7th Allogeneic Cell Therapies Summit eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in